Masana'antar harhada magunguna ta kasance masana'antar rufaffiyar ko da yaushe.Kamfanonin harhada magunguna koyaushe suna rabuwa da duniyar waje ta hanyar hadaddun ilimin kantin magani da ba a raba su ba.Yanzu wannan bangon yana rushewa saboda fasahar dijital. Ƙari da ƙarin kamfanoni masu hankali na wucin gadi sun fara haɗin gwiwa. tare da masu haɓaka magunguna don amfani da fasahar fasaha ta wucin gadi zuwa kowane hanyar haɗin yanar gizo na sabon bincike da haɓaka magunguna da haɓaka sabon tsarin bincike da haɓakar magunguna.
Kwanan nan, AI + sabuwar kasuwar magunguna ta sami labarai mai daɗi akai-akai, kuma kamfanoni da yawa sun kammala babban kuɗi a cikin 2020.
A watan Yuni 2010, The Drug Discovery Today ya buga wani ɗan gajeren bita, "The Upside of Being a Digital Pharma Player", wanda yayi nazari akan halin yanzu na aikace-aikacen AI a cikin sassan R & D na 21 Pharmaceutical Giants a duk duniya daga 2014 zuwa 2018. Sakamakon ya nuna cewa FIELD na AI + sababbin magunguna, kodayake har yanzu a farkon matakansa, yana girma.
Bisa kididdigar da aka yi, ya zuwa ranar 16 ga Oktoba, 2020, jimillar sabbin kamfanonin AI+ 56 a cikin gida da waje sun samu kudade, tare da jimlar kudaden da suka tara dala biliyan 4.581. Daga cikinsu, kamfanoni 37 na kasashen waje sun sami kudade tare da jimlar jimlar. jimlar dalar Amurka 31.65, kuma kamfanoni na cikin gida 19 sun sami tallafi tare da jimlar jimlar dala biliyan 1.416. daloli.
Lokacin aikawa: Nov-03-2020